schliessen

Filtern

 

Bibliotheken

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy

A number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal... Full description

Journal Title: Nanomedicine Nov, 2011, Vol.6(9), p.1645(10)
Main Author: Waterhouse, Dawn N
Other Authors: Yapp, Donald , Verreault, Maite , Anantha, Malathi , Sutherland, Brent , Bally, Marcel B
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 1743-5889
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa284124412
title: Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
format: Article
creator:
  • Waterhouse, Dawn N
  • Yapp, Donald
  • Verreault, Maite
  • Anantha, Malathi
  • Sutherland, Brent
  • Bally, Marcel B
subjects:
  • Colorectal Cancer -- Development And Progression
  • Tumors -- Development And Progression
  • Drug Delivery Systems
  • Chemotherapy
  • Cancer Treatment
ispartof: Nanomedicine, Nov, 2011, Vol.6(9), p.1645(10)
description: A number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal drug delivery systems have the ability to provide a dual mechanism of activity where tumor accumulation can deliver high local concentrations of the drug at the site of action with concomitant slow release of the drug from carriers in the blood compartment that results in antivascular effects, similar to that achieved when dosing frequently at low levels. Although this dual mechanism of activity may be linked to other lipid nanoparticle formulations of anticancer drugs, this article summarizes the evidence supporting direct (cytotoxic) and indirect (antivascular) actions of a liposomal formulation of irinotecan.
language: English
source:
identifier: ISSN: 1743-5889
fulltext: fulltext
issn:
  • 1743-5889
  • 17435889
url: Link


@attributes
ID383747808
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid284124412
sourceidgale_ofa
recordidTN_gale_ofa284124412
sourceformatXML
sourcesystemPC
galeid284124412
display
typearticle
titleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy
creatorWaterhouse, Dawn N ; Yapp, Donald ; Verreault, Maite ; Anantha, Malathi ; Sutherland, Brent ; Bally, Marcel B
ispartofNanomedicine, Nov, 2011, Vol.6(9), p.1645(10)
identifierISSN: 1743-5889
subjectColorectal Cancer -- Development And Progression ; Tumors -- Development And Progression ; Drug Delivery Systems ; Chemotherapy ; Cancer Treatment
languageEnglish
source
descriptionA number of studies have outlined the antiangiogenic effects of cytotoxic agents when administered frequently at low doses. These studies suggest that the effect of the cytotoxic agent is on the vasculature within the tumor and it is assumed that there is little or negligible cytotoxicity. Liposomal drug delivery systems have the ability to provide a dual mechanism of activity where tumor accumulation can deliver high local concentrations of the drug at the site of action with concomitant slow release of the drug from carriers in the blood compartment that results in antivascular effects, similar to that achieved when dosing frequently at low levels. Although this dual mechanism of activity may be linked to other lipid nanoparticle formulations of anticancer drugs, this article summarizes the evidence supporting direct (cytotoxic) and indirect (antivascular) actions of a liposomal formulation of irinotecan.
version3
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefileg
1gale_onefilea
2OneFile
creatorcontrib
0Waterhouse, Dawn N
1Dawn N Waterhouse
2Yapp, Donald
3Verreault, Maite
4Anantha, Malathi
5Sutherland, Brent
6Bally, Marcel B
titleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
subject
0Colorectal cancer--Development and progression
1Tumors--Development and progression
2Pharmaceutical Preparation Manufacturing
3Ambulatory Health Care Services
4325412
5621
6Drugs
7Cancer
general
0English
1Future Medicine Ltd.
2Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa284124412
issn
01743-5889
117435889
rsrctypearticle
creationdate2011
recordtypearticle
addtitleNanomedicine
searchscopeOneFile
lsr30VSR-Enriched:[eissn, galeid, description, doi]
sort
titleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
authorWaterhouse, Dawn N ; Yapp, Donald ; Verreault, Maite ; Anantha, Malathi ; Sutherland, Brent ; Bally, Marcel B
creationdate20111101
facets
frbrgroupid5113931486916919040
frbrtype5
languageeng
creationdate2011
topic
0Colorectal Cancer–Development And Progression
1Tumors–Development And Progression
2Drug Delivery Systems
3Chemotherapy
4Cancer Treatment
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontrib
0Waterhouse, Dawn N
1Yapp, Donald
2Verreault, Maite
3Anantha, Malathi
4Sutherland, Brent
5Bally, Marcel B
jtitleNanomedicine
toplevelpeer_reviewed
frbr
t2
k12011
k217435889
k46
k59
k61645
k7nanomedicine
k8lipid based nanoformulation of irinotecan dual mechanism of action allows for combination chemo angiogenic therapy
k9lipidbasednanoformulerapy
k12lipidbasednanoformulation
k15dawnnwaterhouse
k16waterhousedawnn
delivery
delcategoryRemote Search Resource
fulltextfulltext
ranking
booster11
booster21
pcg_typeaggregator
addata
au
0Waterhouse, Dawn N
1Yapp, Donald
2Verreault, Maite
3Anantha, Malathi
4Sutherland, Brent
5Bally, Marcel B
atitleLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
jtitleNanomedicine
risdate20111101
volume6
issue9
spage1645
issn1743-5889
genrearticle
ristypeJOUR
pubFuture Medicine Ltd.
lad01gale_ofa
doi10.2217/nnm.11.140
eissn17486963
date2011-11-01